Rezolute, Inc.
corporate_fare Company Profile
Rezolute, Inc. (NASDAQ:RZLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for RZLT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for RZLT spans FWP, 424B5, 8-K, 10-K.
Recent high-impact activity:
- Rezolute Prices $100M Offering as Lead Drug Hits Phase 3 Efficacy Goal
- Rezolute Prices $100M Offering at $3.87/Share, Led by Frazier Life Sciences
- Rezolute Launches Underwritten Stock and Pre-Funded Warrant Offering Days After $400M Shelf
- Rezolute's upLIFT Phase 3 Hits Primary Endpoint in Tumor Hyperinsulinism
- Rezolute Launches Underwritten Stock and Pre-Funded Warrant Offering Days After $400M Shelf
Financial Snapshot
Short Interest & Short Volume
14.93 days to coverFINRA reported short interest of 18,498,517 shares in RZLT as of the October 30, 2026 settlement, a 3.5% decrease from the prior period — about 14.9 days to cover at its recent average daily volume. On November 20, 2026, 49.3% of RZLT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RZLT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.
Offering Priced at $3.87 per Share · Dilution Adds ~25.8M Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →